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Abstract. We have evaluated the potential usefulness 
of the radioiodinated octapeptide RC-160, a somatosta- 
tin analogue, which might serve as a radiopharmaceu- 
tical for the in vivo detection of somatostatin receptor- 
positive tumours. For this purpose, iodine-123 and io- 
dine-125 labelled RC-160 was tested for biological ac- 
tivity and applied in vivo in rats bearing the transplan- 
table rat pancreatic tumour CA20948, which expresses 
somatostatin receptors. Our group has recently de- 
scribed the in vivo visualization of such tumours in rats 
and in humans with the radioiodinated somatostatin a a- 
logue [Tyr3]octreotide. Like [123I-Tyr3]octreotide, 123I- 
RC-160 showed uptake in and specific binding in vivo 
to somatostatin receptor-positive organs and tumours. 
However, blood radioactivity (background) was higher, 
resulting in a lower tumour to blood (background) ratio. 
We therefore conclude that in this animal model 123I- 
RC-160 has no advantage over [~23I-Tyr3]octreotide as
a radiopharmaceutical for the in vivo use as a somato- 
statin receptor imager, although, like [~23I-Tyr3]octreo- 
tide, 123I-RC-160 shows specific binding to different so- 
matostatin receptor-positive organs. Recently differ- 
ences were reported in affinity between somatostatin 
and its analogues for somatostatin receptors expressed 
in different human cancers, like those of the breast, 
ovary, exocrine pancreas, prostate and colon. Therefore 
~23I-RC-160 might be of interest for future use in hu- 
mans as a radiopharmaceutical for imaging octreotide 
receptor-negative tumours. 
Key words: Radioiodinated RC-160 - Somatostatin - 
Specific binding - Tumour imager - Peptide 
Eur J Nucl Med (1993) 20:1089-1094 
Correspondence to: W.A.P. Breeman, Department of Nuclear 
Medicine, University Hospital Dijkzigt, Dr. Molewater~plein 40,
NL-3015 GD Rotterdam, The Netherlands 
Introduction 
High numbers of high-affinity somatostatin receptors 
for both native somatostatin (for structure, see Fig.l) 
and the synthetic octapeptide octreotide (Sandostatin) 
have been detected on most endocrine tumours, such as 
endocrine pancreatic tumours and carcinoids [1-4]. We 
have recently described the visualization of somatosta- 
tin receptor-positive tumours in vivo after the intrave- 
nous administration of [123I-Tyr3]octreotide [5-9], and 
these results have been confirmed by others [10-12]. 
Radioiodinated [Tyr3]octreotide is frequently used for 
the in vitro determination of the presence of somatosta- 
tin receptors [13]. Recently, several reports have been 
published on the in vitro binding to somatostatin recep- 
tors of another somatostatin analogue, the octapeptide 
RC-160 [14-16]. It has been reported that RC-160 has 
a higher affinity than octreotide for the somatostatin re- 
ceptor in human breast, ovarian, exocrine pancreatic, 
prostatic and colonic cancers [14-16]. A phase 1 clinical 
trial with RC-160 in patients with advanced exocrine 
pancreatic cancer is being performed, and it appears that 
RC-160 is well tolerated at doses up to 1500 gg/day 
[17, 18]. The possibility of RC-160 binding to a soma- 
tostatin receptor subtype on human exocrine pancreatic 
adenocarcinoma, which does not bind octreotide [19], 
offers a potential advantage for RC-160 over octreotide 
as a radiolabelled tumour tracer. RC-160 may, in con- 
trast to octreotide [20], also pass the blood-brain barrier 
[21]. This could represent a benefit in visualizing so- 
matostatin receptor-positive brain tumours with an in- 
tact blood-brain barrier. We investigated radioiodinated 
RC-160 (for structure, see Fig. 1) for potential use in 
scintigraphy in normal rats and in rats bearing the trans- 
plantable pancreatic somatostatin receptor-positive tu- 
mour CA20948 [13, 19, 22]. A comparison was made 
with [~23I-Tyr3]octreotide, and the possible additional 
value of I23I-RC-160 as a radiopharmaceutical was 
evaluated. 
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Somatostatin 
[ I 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys 
Octreotide 
I I 
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol) 
[mI-Tyr3]octreotide 
I I 
H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol) 
I 
1231 
mI-RC-160 
I I 
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 
I 
123 I 
Fig. 1. Stuctural formulae of native somatostatin, octreotide, [~23I- 
Tyr3]octreotide and 123I-RC-160. In [Tyr3]octreotide the amino 
acid Tyr replaces Phe to make radioiodination possible. In RC-160 
Tyr is naturally present 
Materials and methods 
Radiopharmaceuticals. RC-160 was obtained from Peninsula 
Laboratories (Belmont, Calif., USA). Radioiodination a d purifi- 
cation was performed using the technique described by Bakker 
[6]. 
[Tyr3]octreotide and RC-160 were labelled with 123I- (specific 
123 125 activity 3.7 TBq I-/mg, Medgenix, Belgium) and I (specific 
125 activity 0.62 TBq I/mg, Amersham, UK). For the in vivo stud- 
ies we used the somatostatin analogues labelled with 123I. The in 
vitro binding studies were performed with (HPLC)-high-perform- 
ance liquid chromatography purified mono-iodinated somatostatin 
analogues, since carrier-free radioligands are required for these 
assays. The radioiodination was carried out by adding 2.5 gg RC- 
160 in 35 ~tl 0.05 M acetic acid and 1.6 gg chloramine-T in 20 
~tl 0.05 M phosphate buffer (pH 7.5) to 200 MBq (=60 gl) 123I 
or 80 MBq (20 gl) 125I in the form of sodium iodide. The reaction 
was started by the addition of chloramine-T, representing anonly 
2.5-fold molar excess over peptide in order to prevent oxidation 
of the disulphide-bridge of RC-160. The mixture was then vor- 
texed for 1 min. The radioiodination was stopped by adding 1 ml 
10% human serum albumin (Merieux, Lyon, France). After vor- 
texing for 30 s, 20 ml 5 mM ammonium acetate was added. Pu- 
rification was performed using a SEP-PAK C18 reversed-phase 
extraction cartridge (Waters Associates, Milford, Mass., USA), 
which was washed with 5 ml 70% ethanol, 5 ml 2-propanol and 
5 ml distilled water. After application of the sample, the SEP-PAK 
cartridge was washed with 5 ml distilled water and radioiodinated 
RC-160 was eluted with 5 ml 96% ethanol. The solvent was 
evaporated at 40°C under a gentle stream of nitrogen. The residue 
(approximately 0.5 ml) was diluted with 2.5 ml 154 mM NaC1 
and 0.05 M acetic acid (pH 3), and the mixture was passed 
through a low protein-binding 0.22-~tm Millex-GV filter (Milli- 
pore, Milford, Mass., USA). The labelling of [Tyr3]octreotide and 
the measurements of radioactivity in all fractions were carried out 
as described previously [6]. The 123I-labelled somatostatin a a- 
logues for in vivo use were not purified by HPLC and, hence, 
consisted of mixtures of mono- and di-radioiodinated and non- 
iodinated peptides (see Results, RadioIabelling of RC-160). All 
chemicals used were of the highest purity available. 
Biological activity. The biological activity of HPLC-purified 
mono- 125I-RC-160 and [125I-Tyr3]octreotide was assessed by 
measuring their potency to inhibit he secretion of rat growth or- 
mone (rGH) from cultured rat pituitary cells as described pre- 
viously [23]. 
Animals and tumours. Twenty-four male Lewis rats (250-300 g) 
were inoculated in both upper hind legs with the transplantable 
rat pancreatic tumour CA20948, which has previously been 
shown to possess omatostatin receptors [19]. Sixteen male Lewis 
rats (250-300 g) without umour were used as controls. The rats 
were anaesthetized with ether. The radiopharmaceuticals were in- 
jected into the dorsal vein of the penis, using siliconized syringes 
(Sigmacoat, Sigma, St. Louis, Mo., USA). The dose was 18.5 
MBq (0.5 ~tg) for the 123I-analogue. The radioactivity of the syr- 
inges was measured in a dose calibrator (VDC-202, Veenstra, 
Joure, The Netherlands) in a standard geometry before and after 
the injection. 
In order to study the organ distribution of 123I-RC-160 and 
[123I-Tyr3]octreotide in the 16 control rats, the rats were allocated 
to two groups for each radiopharmaceutical. Four rats were in- 
jected subcutaneously between the scapulae with ml 0.01 M acetic 
acid containing 154 mM NaC1, and four other rats were injected 
with 1 mg RC-160 in the same solvent in order to saturate the 
somatostatin receptors. Forty-five minutes later the rats were in- 
jected with 123I-RC-160. Similarly, the two other groups of four 
rats were pretreated with vehicle or 1 mg octreotide and were 
subsequently injected intravenously with [123I-Tyr3]octreotide. 
The rats were killed 4 h after administration f 123I-RC-160 or 
[123I-Tyr3]octreotide. 
The 24 tumour-bearing Lewis rats were divided into three 
groups of eight rats. In each group four rats were injected sub- 
cutaneously with 1 mg RC-160 in order to saturate the somato- 
statin receptor, as mentioned above. The three groups of eight 
rats were killed at 30 min, 4 h or 24 h after administration f 
123I-RC-160. The radioactivity concentration i  various tissues 
was subsequently measured. 
The specific binding was defined as the difference between 
the individual uptake in the non-saturated tissues and the mean 
uptake in the saturated tissues, which are expressed as percentages 
of the injected radioactivity per gram tissue in the respective or- 
gans (mean + SD) after administration f 123I-RC-160 or [123I- 
Tyr 3] octreotide. 
Data acquisition and statistical analysis. All results are expressed 
as the mean + SD. Tissue-binding values and effects on rat growth 
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hormone secretion f r both radiolabelled peptides were evaluated 
using Student's t-test. A P value of <0.05 was considered signif- 
icant. The tissue distribution and metabolism of 123I-RC-160 and 
[~23I-Tyr3]octreotide in vivo were studied by gamma camera 
(Rota-II, Siemens) scintigraphy and measurement of isolated or- 
gans in a LKB-1282-Compugammasystem [6]. The radioactivity 
in blood and urine was analysed as described previously [6]. 
Results 
Radiolabelling of RC-160 
The efficiency of labelling of RC-160 was 40%-60% 
for 125I and 70%-90% for 123I, in agreement with the 
radioiodination data for [Tyr3]octreotide, as described 
previously [6]. Purification of the iodination mixture us- 
ing the SEP-PAK C18 reversed-phase cartridge resulted 
in mainly non-peptide-bound radioiodine in the water 
fraction and more than 99% peptide-bound radioiodine 
in the ethanol fraction, revealed by HPLC. In Fig. 2 a 
typical HPLC elution pattern of the peptides eluted in 
the ethanol fraction is show, indicating a radiochemical 
purity of more than 95% of mono-radioiodinated RC- 
160. The simultaneously measured absorbance at 254 
nm and radioactivity show a clear separation between 
radioiodinated RC- 160 and non-radioiodinated RC- 160. 
The acetic acid wash, included in the SEP-PAK pu- 
rification of [123I-Tyr3]octreotide, was omitted from the 
isolation procedure for 123I-RC-160, since this wash was 
found already to contain a substantial fraction &-5%- 
10%) of the radioiodinated RC-160, while only negli- 
gible amounts of free radioiodide were detected. 
Since the radiolabelling and the SEP-PAK C18 sepa- 
ration technique appeared adequate (more than 95% ra- 
diochemical purity of mono-radioiodinated [Tyr3]oc - 
treotide and RC-160), HPLC purification of the radio- 
labelled somatostatin analogues was not performed. 
These results were in agreement with the radiolabelling 
results of [Tyr3]octreotide [6]. 
Receptor binding and specific biological activity 
Table 1 shows the effects of 125I-RC-160 and [125I- 
Tyr3]octreotide on the secretion of rGH by cultured rat 
pituitary cells. Both iodinated somatostatin analogues 
significantly inhibited rGH secretion at 1 nM. Both ra- 
dioiodinated analogues caused a similar dose-response 
as the non-radioiodinated counterparts (data not shown). 
Animal studies 
Dynamic scintigraphy of tumour-bearing and control 
rats after i.v. administration of 123I-RC-160 and [123I- 
Tyr3]octreotide showed a fast disappearance of the ra- 
dioactivity from the circulation. With both radioiodi- 
nated analogues radioactivity in the blood circulation, 
120 
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Fig. 2. HPLC-elution pattern of the ethanol fraction of SEP-PAK 
C18 purification. Non-radioiodinated RC-160 is measured by UV 
absorbance (~=254 nm, broken line), radioiodinated RC-160 and 
free radioiodide by gamma detection (solid line). Th  gamma de- 
tected peak at 27 rain is the di-iodinated compound 
Table 1. Effects of 125I-RC-160 and [125I-Tyr3]octreotide on se- 
cretion of rGH from cultured rat pituitary cells (n=4) 
Peptide Concentration rGH 
(rul//) (ng/ml + SD) (%) 
Control 
125I_RC - 160 
[ 125 I_Tyr 3]octreotide 
89.1 + 9.0 (100) 
0.01 91.7 + 4.6 (103) 
0.1 95.5 + 3.0 (107) 
l 77.2 + 11.1 (87)* 
0.0l 90.0 _+ 4.8 (101) 
0.1 79.9 + 11.3 (90) 
l 64.8 + 4.6 (73)* 
* P< 0.05 vs control 
as measured above the heart with the gamma camera, 
decreased in less than 2 rain to 50% of the highest mea- 
sured radioactivity. This rapid fall in the blood activity 
can be explained by the phenomenon of distribution of 
the activity over the whole blood and the interstitial 
space. 
Thirty minutes after injection static images showed 
a clear uptake of radioactivity in the liver and intestines. 
The left kidney was seen, as well as excreted activity 
in the urinary bladder. The right kidney was overpro- 
jected by the liver. 
Dynamic tumour uptake in situ in the rat during the 
first 30 min after injection of 123I-RC-160 was analysed 
with the gamma camera. After background correction, 
using adjacent issue as reference, no increased uptake 
in the tumour was found, whereas specific binding in 
the isolated tumour became statistically significant at 4 
h (Table 2). As can be seen in Table 2, there was sig- 
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Table 2. Tissue distribution (% of injected dose/g tissue) and 
specific binding (A) of ~23I-RCq60 in tumour~bearing rats after 
intravenous administration (mean + SD)" 
Tissue 0.5 h p.i. 4 h p.i. 24 h p.i. 
Pancreas - 0.91 -+ 0.38 0.32 _+ 0.08 0.06 -+ 0.02 
+ 0.10 _+ 0.01 0,07 _+ 0.02 0.021 _+ 0.002 
A 0.81 _+ 0.38* 0.25 +_ 0.08* 0.040 + 0.019' 
Adrenals - 1.17 _+ 0.06 0.54 _+_ 0.09 0.06 + 0.03 
+ 0.20 _+ 0.06 0.07 +_ 0.01 0.038 _+ 0.009 
A 0.97 +_ 0.06* 0.47 _+ 0.09* 0.022 _+ 0.028 
Pituitary - 0.16 + 0.06 0.08 _+ 0.02 0.05 _+ 0.05 
+ 0.021 _+ 0.003 0.013 _+ 0.002 0.004 _+ 0.000 
A 0.13 _+ 0.06* 0.064_+ 0.020* .044 _+ 0,048 
Brain - 0.014_+ 0.002 0.008 _+ 0.002 0.0019 + 0.0009 
cortex + 0.008 + 0.001 0.003 _+ 0.000 0.0013 _+ 0.0003 
A 0.007 + 0.003* 0.005 + 0.002* 0.0006 + 0.0009 
Tumour - 0.23 _+ 0.07 0.20 + 0.05 0.037 + 0.021 
+ 0.11 _+ 0.02 0.08 + 0.02 0.036 + 0.003 
A 0.11 _+ 0.07 0.12 _+ 0.05* 0.001 _+ 0.021 
Kidneys - 0.74 + 0.13 0.43 + 0.13 0.11 _+ 0.03 
+ 0.53 + 0.04 0.22 + 0.05 0.10 + 0.02 
A 0.21 +_ 0.13 0.21 + 0.13 0.01 + 0.03 
* P< 0.01, specific binding significantly different from zero 
a Each group contained four rats: -, no pretreatment; +, pretreat- 
ment with 1 mg unlabelled RC-160 subcutaneously 45 min prior 
to the injection of 123I-RC-160 
Table 3. Tissue distribution [with (+) and without (-) pretreat- 
merit of rats with unlabelled RC-160] and specific binding (A) in 
somatostatin receptor-positive organs (mean _+ SD) in non-tu- 
rnout-bearing rats (n=4), 4 h after injection of ~23I-RC-160. The 
rats in the parallel experiment with [lz3I-Tyr3]octretide w re pre- 
treated with 1 mg octreotide 
Tissue 123I-RC- 160 [ 123i_Tyr3 ]OctreOtide 
Pancreas - 0.2l _+ 0.05* 1.03 _+ 0.15 
+ 0.025 + 0.006 0.023 _+ 0.002 
A 0.17 + 0 05* ** • ' 1.01 _+ 0.15"*  
Adrenals 
Pituitary 
- 0.19 + 0.03* 0.26 + 0.02 
+ 0.042 + 0.010 0.027 + 0.002 
A 0.15 _+ 0.03*'** 0.23 _+ 0.02** 
- 0.066 + 0.007* 0.32 + 0.09 
+ 0.0078 -+ 0.0020 0.0067 + 0.001 
A 0.063 _+ 0.007*'** 0.31 + 0.09** 
Brain - 0.0052 + 0.0014" 0.0019 +_0.0002 
cortex + 0.0019 _+ 0.0003 0.0012 _+ 0.0002 
A 0.0033 -+ 0.0014"** 0.0007 _+0.0002 
* P< 0.01, 123I-RC-160 vs [123I-Tyr3]octreotide 
** P< 0.01, specific binding significantly different from zero 
Tab le  4. Tissue distribution (% of injected dose/g tissue, mean 
+ SD) in tumour-bearing rats (n=4) 24 h after intravenous injec- 
tion of 0.5 gg radioiodinated somatostatin analogue 
Tissue 123I-RC-160 [123I-Tyr3]octreotide 
Spleen 0.06 _+ 0.03 0.028 + 0.021 
Kidneys 0.12 _+ 0.03 0.13 _+ 0.01 
Liver 0.17 ___ 0.03* 0.027 + 0.005 
Intestines 0.2 + 0.0* 0.03 + 0.01 
Thyroid 320 _+ 70 180 _+ 50 
Thymus 0.068 -+ 0.032 ~ 0.016 + 0.007 
Lungs 0.12 + 0.04* 0.033 _+ 0.006 
Blood 0.13 + 0.08* 0.006 _+ 0.000 
Pancreas 0.06 + 0.02 0.11 + 0.04 
Adrenals 0.06 + 0.03 0.04 _+ 0.01 
Pituitary 0.05 + 0.05* 0.17 + 0.02 
Brain cortex 0.0019 + 0.0009 0.002 + 0.001 
Tumour 0.037 + 0.021" 0.007 + 0.001 
* P< 0.01, 123I-RC-160 vs [~23I-Tyr3]octreotide 
nif icant specif ic b inding in all the somatostat in recep- 
tor- posit ive tissues analysed, i.e. pancreas, adrenals, pi- 
tuitary and brain cortex, at 0.5 and 4 h, and in the tu- 
mour at 4 h after injection. After 24 h there was still 
signif icant specific binding in the pancreas. F rom 30 
min after the administration of 123I-RC-160, total radio- 
activity d isappeared rapidly from the measured organs 
and tumours. Statist ical ly signif icant specif ic binding 
was still present 24 h after [~23I-Tyr~]octreotide inj ct ion 
in the pancreas, adrenal and pituitary gland (data not 
shown). 
In Table 3 the tissue distr ibutions, 4 h after injection, 
are compared between pretreated and non-pretreated, 
non-tumour-bear ing rats. We found a higher uptake of 
[~23I-Tyr3]octreotide n the adrenals, the pancreas and the 
pituitary gland, than was found when using 123I-RC-160. 
The effect of  pretreatment with unlabel led RC-160 or 
octreotide is evident in the somatostatin receptor-posi-  
t ive organs for both ~23I-RC-160 and [~23I-Tyrg]octreo - 
tide. Signif icant ly higher specif ic binding of  radioact iv-  
ity was found after administrat ion of  [~23I-Tyr~]octreo- 
tide in the adrenals, the pancreas and the pituitary gland 
than after administrat ion of  ~23I-RC-160. In the rat brain 
cortex 123I-RC-160 has a higher uptake and specif ic 
binding than [~z3I-Tyr~loctreotide. 
Urine samples were obtained 30 min p.i. f rom tu- 
mour-bear ing rats (n=4), showing 13% + 1% of the total 
radioact iv i ty in the form of  pept ide-bound radioiodine. 
Twenty-four hours p.i. the percentage of  pept ide-bound 
radioiodine in urine and b lood had dropped to 1.3% + 
0.2% and 1.1% + 0.3%, respectively, and more than 
95% of the radioact iv i ty in the urine was free radioio-  
dine, which is comparable with the results obtained us- 
ing [x23I-Tyr3]octreotide as radio l igand (data not shown). 
A compar ison of  the tissue radioact iv i ty concentra- 
tions 24 h after inject ion of  123I-RC-160 and [~23I- 
Tyr3]octreotide is presented in Table 4. [la3I-Tyr3]octreo- 
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tide had a higher clearance of radioactivity from soma- 
tostatin receptor-negative tissues, such as liver, thymus, 
blood and lungs, and a significantly higher binding in
the somatostatin receptor-positive pituitary than 123I-RC- 
160. Only in the tumour was there significantly higher 
binding of radioactivity for 123I-RC-160 compared to 
[123I-Tyr3]octreotide, but as can be seen from Table 2, 
this was not specific binding. 
Discussion 
RC-160 is, like octreotide, a somatostatin analogue with 
potent hormone secretion-inhibiting characteristics in 
vivo and in vitro. However, discrepancies with octreo- 
tide have been described, especially with regard to bind- 
ing to a number of human cancers, like those of the 
breast, ovary, exocrine pancreas, prostate and colon 
[ 14-18, 21 ]. Therefore, radioiodinated RC- 160 might be 
an important radiopharmaceutical, having potential ad- 
vantages over radioiodinated octreotide for the in vivo 
detection of the aforementioned somatostatin receptor- 
positive tumours. In the literature no data are available 
on tissue distribution of the somatostatin analogue RC- 
160, either in animals or in humans. In the present 
study, therefore, we evaluated the potential use of radi- 
ioiodinated RC-160 for somatostatin receptor scintigra- 
phy. There was significantly higher uptake and specific 
binding in somatostatin receptor-positive organs, such 
as the pancreas, the adrenal and the anterior pituitary 
gland, of 123I after administration of [123I-Tyr3]octreotide 
than after 123I-RC-160. 
In brain cortex of control rats we found at 4 h a low, 
but statistically significant specific binding of 123I-RC- 
160. However, this was caused by a very low amount 
of tracer (0.0052% of injected dose per gram) in com- 
parison with other somatostatin receptor-positive tis- 
sues, such as the pancreas (0.21% of injected dose per 
gram). Since we found a significant difference between 
the uptake of radioactivity in saturated and non-satu- 
rated brain cortex, these data suggest hat, in contrast 
to octreotide, RC-160 and radioiodinated RC-160 are 
able to cross the blood-brain barrier, as has also been 
reported for cold RC-160 and radioiodinated RC-160 
by Banks et al. [21, 24]. The presence of the C-terminal 
amino acid tryptophan i  RC-160 (see Fig. 1) enhances 
the lipophilicity of the molecule, and this might also 
explain its increased blood-brain barrier permeability 
and reduced clearance from the tissues and blood. 
During the first 30 rain after the injection of 123I-RC- 
160 there was no statistically significant uptake in the 
tumour as measured by gamma camera scintigraphy, nor 
was there any after background correction. This finding 
is in contrast with the results of the experiments with 
[123I-Tyr3]octreotide as described by Bakker et al. [6]. 
However, 30 min after the injection of ~a3I-RC-160, sta- 
tistically significant specific binding in the isolated tu- 
mour was found. Since there is no significant difference 
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between the uptake or specific binding after the injec- 
tion of [123I-Tyr3]octreotide and 123I-RC-160 in the iso- 
lated tumour at 30 rain, the relatively low tumour to 
blood ratio in these experiments i probably the reason 
for this discrepancy. 
To conclude: 123I-RC-160 does not seem to have ad- 
vantages over [l~3I-Tyr3]octreotide as a radiopharmaceu- 
tical for somatostatin-receptor scintigraphy, despite the 
fact that 123I-RC-160 shows specific high-affinity bind- 
ing to various somatostatin receptor-positive organs. In 
contrast o radioiodinated [Tyr3]octreotide and octreo- 
tide, which do not pass the blood-brain barrier, our ex- 
periments confirm that RC-160 and radioiodinated RC- 
160 indeed do pass the blood-brain barrier. However, 
this occurs in low quantities, and consequently the ap- 
plication of radioiodinated RC-160 in nuclear medicine 
for visualizing somatostatin receptor-positive brain tu- 
mours with an intact blood-brain barrier is hampered. 
In comparison with [123I-Tyr3]octreotide, the main dis- 
advantage of 123I-RC-160 is its relatively low tumour to 
blood (background) ratio, implying poorer in vivo tu- 
mour detection. 
Apart from the discussed ata, it must be emphasized 
that several authors have reported that in comparison to 
octreotide, RC- 160 has superior binding characteristics 
in some human tumours. Therefore, RC-160 and, in 
spite of its disadvantages, 123I-RC-160 could open new 
diagnostic and/or therapeutic applications in patients 
bearing such tumours. Consequently, in analogy to the 
development of the indium- l 11 labelled [DTPA-D- 
Phel]octreotide analogue, 111In-labelled [DTPA-D- 
PheI]RC-160 is being prepared and investigated. 
The authors wish to thank Dr. Wil Kort, Ineke Hekking-Weyma, 
Reno Mekes, Marcello Harms and In  Loeve for their expert as- 
sistance during the experiments. 
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